J&J says its one-shot COVID-19 vaccine is 72% effective in the U.S.

J&J says its one-shot COVID-19 vaccine is 72% effective in the U.S.

January 29, 2021: Johnson & Johnson said on Friday that its one-dose coronavirus vaccine was 72% effective in the United States. Whereas the vaccine was less potent in other regions, it said.
The highly anticipated results were based on 468 confirmed Covid-19 infections among the phase three trials more than 43,000 volunteers, according to J&J.
The level of protection varied by region, J&J said, with the vaccine demonstrating 66% effectiveness overall, 72% in the United States, 66% in Latin America, and 57% in South Africa after four weeks.
“We’re proud to have reached this critical milestone, and our commitment to address this global health crisis continues with urgency for everyone, everywhere,” J&J CEO Alex Gorsky said.
The vaccine was well tolerated, with no significant safety concerns related to the immunization reported, J&J said. There were also no reports of anaphylaxis.
U.S. officials and Wall Street analysts are anticipating J&J’s vaccine’s authorization, which could happen next month.
The Food and Drug Administration has indicated it would authorize a vaccine that’s safe and at least 50% effective. According to the CDC, the flu vaccine generally reduces people’s risk of getting influenza by 40% to 60% compared with people who aren’t inoculated
.
If the FDA authorizes J&J’s vaccine, it would be the third approved for emergency use in the U.S. except for the Pfizer-BioNTech vaccine and Moderna’s vaccine.
J&J’s requires only one dose, which means patients will not have to come back for another dose, simplifying logistics for health-care providers. Additionally, J&J has said it plans to ship the vaccine between 2 to 8 degrees Celsius, which is about 36 to 46 degrees Fahrenheit.
In August, the Department of Health and Human Services announced that it reached a deal with Janssen, J&J’s pharmaceutical subsidiary, worth approximately $1 billion for 100 million doses of its vaccine. According to the announcement, the agreement gives the federal government the option to order an additional 200 million doses.

Share on facebook
Share on google
Share on twitter
Share on linkedin
About Us
We provide the insights on leaders who are responsible for taking their organization to new heights, all the while bringing together a group of talented individuals.
Recent Posts